Clinical trial
Determine Whether Glycemic Control is Different Between Lantus & a 3rd Oral…
NCT00046462 · Sanofi, Industry · Completed
Key facts
| NCT number | NCT00046462 |
|---|---|
| Title | Determine Whether Glycemic Control is Different Between Lantus & a 3rd Oral Agent When Failure With Other Treatment |
| Official title | Substituting Lantus®(Insulin Glargine[rDNAorigin]Inj) for a Thiazolidinedione vs. a 3rd Oral Agent as add-on Therapy in Patients Failing a Thiazolidinedione & Sulfonylurea or Metformin Combination |
| Lead sponsor | Sanofi, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Diabetes Mellitus |
| Intervention type | Drug |
| Interventions | Lantus (insulin glargine [rDNA origin] injection), Metformin, Glyburide, Thiazolidinedione |
| Enrollment | 240 |
| Start date | Nov 1, 2001 |
| Primary completion | Nov 1, 2004 |
| Completion | Dec 1, 2004 |
| First posted | Oct 2, 2002 |
| Last update posted | Jan 11, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: